Q3 2023 Results - Reimagining Medicine slide image

Q3 2023 Results - Reimagining Medicine

Company overview Innovation: Pipeline overview Cardiovascular Financial review Conclusions Financial performance Immunology Immunology Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 52 Investor Relations | Q3 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation